CLOs on the Move

IntelGenx

www.intelgenx.com

 
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.intelgenx.com
  • 6420 Rue Abrams
    Saint-Laurent, QC CAN H4S 1Y2
  • Phone: 514.331.7440

Executives

Name Title Contact Details
Tommy Kenny
Vice President of Intellectual Property and Legal Affairs and General Counsel Profile

Similar Companies

Germiphene Corporation

Germiphene Corporation is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

Connecticut Orthopaedics

Connecticut Orthopaedics is a premier team of orthopaedic doctors, surgeons and health care professionals that keep you moving forward with life. Learn more

Auxillium East

Auxillium East is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Citizens Rx

Citizens Rx provides pharmacy benefit management services to public and private companies and offers health plans in the United States.